Moderna, Inc. (BVL:MRNAUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 85.90B +125.0% |
| Revenue (ttm) | 7.77B -30.0% |
| Net Income | -11.15B |
| EPS | -28.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 52.13 |
| Day's Range | n/a |
| 52-Week Range | 27.29 - 54.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 5...
Moderna announces FDA advisory committee votes in favor of mRNA-1010
Moderna (MRNA) announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010, Moderna’s investigational se...
Moderna up 4% after FDA advisers back flu vaccine approval
Shares of Moderna (MRNA) are up $2.48, or 4%, to $64.28 in afternoon trading after members of the FDA’s Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor…
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Ad...
Jefferies’ confidence in Moderna’s mRNA flu shot rises after AdCom support
Jefferies reiterated a Hold rating and $45 price target on Moderna (MRNA) after the FDA’s Advisory Committee voted 9-0 in favor of a full approval for Moderna’s mFLUSIVA mRNA seasonal…
US FDA advisers vote in favor of Moderna's flu vaccine
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vaccine in adults aged 50 and older, saying its benefits outweigh the risks.
FDA panel backs Moderna mRNA-based influenza vaccine, Bloomberg reports
FDA advisers note benefits of Moderna’s (MRNA) flu vaccine outweigh the risks in adults aged between 50 and 64 and said the benefits outweigh the risks in adults aged 65…
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course on rejectin...
Moderna to Host Investor Event - Science Day
CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026. The event will...
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel tol...
BofA says VRBPAC docs look supportive but keeps Moderna at Underperform
BofA reviewed the VRBPAC briefing docs released this morning. Overall, the tone of the documents and proposed points of focus should foster some debate but look supportive for approval, the…
FDA posts briefing docs for meeting to discuss Moderna influenza vaccine
On June 18, the FDA is convening a meeting of the Vaccines and Related Biological Products Advisory Committee to discuss the benefit-risk assessment of mFlusiva, an mRNA-based trivalent influenza vacc...
Moderna flu vaccine briefing docs ‘read favorably,’ says Jefferies
Ahead of the FDA hosting an advisory committee meeting on Moderna’s (MRNA) mFLUSIVA mRNA vaccine for seasonal flu on Thursday, Jefferies says the firm finds the FDA’s tone and analyses…
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults
The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may support effectiveness in adults 65 years and older.
Moderna announces executive changes ahead of potential launches
Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, the vaccine maker said on Tuesday, as it prepares for potential product launches over...
Moderna president Stephen Hoge to assume expanded role, Ester Banque named CCO
Moderna (MRNA) announced changes to its operating model to support its short- and long-term business goals. As Moderna executes its long-range plan to become a diversified, multi-modality biotechnolog...
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises Ester Banque to Join Moderna a...
Moderna Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy focused on global expansion, product diversification, and disciplined cost control, targeting up to 10% revenue growth and cash flow breakeven by 2028. Key pipeline assets, including intismeran and a norovirus vaccine, are expected to drive substantial future growth, with new launches and market share gains in both the U.S. and Europe.
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration between the Universi...
Moderna price target raised to $34 from $32 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $34 from $32 and keeps an Underperform rating on the shares after having hosted Moderna’s CEO for a group lunch.
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna custome...
Moderna to Present at Upcoming Conference in June 2026
CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Goldman Sachs 47th Annual Global Healthca...
Moderna Transcript: Study update
Intismeran, an individualized mRNA neoantigen therapy, showed a 49% reduction in recurrence risk and strong safety in phase II melanoma trials. Mechanistic data confirmed robust, durable T cell responses linked to efficacy, supporting expansion to other cancers and large-scale manufacturing.
Moderna Press release: Study update
Moderna issued a press release on June 1, 2026, disclosing material business information to investors.